UN Peacekeeping Mission Helicopter Shot Down In NE DR Congo

KINSHASA, Mar 30 (NNN-IRIN) – A helicopter of the United Nations Organisation Stabilisation Mission, in the Democratic Republic of the Congo (DRC), or MONUSCO, was shot down yesterday, by rebels of the March 23 Movement (M23), with eight people on board, said the DRC armed forces (FARDC).

The tragedy took place as several FARDC military positions had been attacked since early Monday by M23 rebels, in the Rutshuru territory of the north-eastern North Kivu province, the same area where the MONUSCO helicopter crashed.

“The helicopter was shot down in the midst of a mission to assess the population movements, caused by the M23 attacks in the region for humanitarian actions,” read the statement issued by the military governor of North Kivu, while accusing the M23 of having shot down the plane, in an area where rebels are staging an offensive.

According to the statement, the downed helicopter had eight peacekeepers and UN observers on board. For the moment, the military authorities have indicated that they are working hard to find the wreckage of the downed aircraft and survivors.

According to a MONUSCO briefing, released earlier, the helicopter, which was on a reconnaissance mission, crashed around noon, local time. The MONUSCO has not yet confirmed the FARDC accusations and the casualty.

The M23 is a group of former rebels of the National Congress for the Defence of the People (CNDP). The name came from the March 23, 2009, agreement between the CNDP and the Congolese government, which M23 leaders claimed had not been respected by the government.

The cause of the air crash remains unknown, and a search-and-rescue mission is underway.

Source: NAM NEWS NETWORK

Amnesty: Failure to Fairly Distribute COVID Vaccines Cost African Lives

Rights group Amnesty International has issued a scathing report on the failure of global drug companies and Western governments to quickly provide COVID vaccines to millions of people in Africa. In its annual report, Amnesty says tens of thousands of deaths could have been prevented if companies put people before profits and if governments were less nationalistic.

In its report for 2021, Amnesty International says Africa was discriminated against by wealthy nations and international corporations who failed to quickly distribute COVID-19 vaccines.

Speaking in Nairobi, Deputy Regional Director of Amnesty International East Africa Sarah Jackson said African countries were among the last to get the vaccines.

“We see a global system that has prioritized vaccines for the few, that have prioritized vaccines for wealthy countries, and it’s been very limited vaccine rollout in this region,” Jackson said. “And yet at the same time, there are a host of lots of problems that has arisen in the way in which vaccines have been distributed that often come in at short notice with very limited expiry dates, and this makes it very difficult for governments to build effective information campaigns to overcome distrust, misinformation that is prevalence in some segments of the population.”

African governments have struggled to purchase vaccines in the global market due to high demand and scarcity. Some African countries accused wealthy nations of hoarding vaccines.

Erastus Mwencha, a former deputy chairperson of the African Union Commission, echoes that view.

“’Apartheidism’ of vaccines you saw in the global north, vaccines that were expiring went to global south. In other words, Africa is seen as a nuisance value,” Mwencha said. “But yet if you think of the pandemic, there is no way the rest of the world can be happy if Africa is sick.”

In its effort to make vaccines more available on the continent, the Africa Centers for Disease Control has pushed for greater production of vaccines on the continent.

The push has paid off as American pharmaceutical giant Moderna is expected to set up vaccine production plants in five African countries.

The Amnesty report praised Rwanda for vaccinating 40 percent of its population. Researchers were also encouraged by the effort of Burundian and Tanzanian authorities to focus more on the pandemic after they initially rejected health measures to contain the virus.

Still, only 10 percent of Africans are vaccinated, the lowest rate among all the world’s continents.

Amnesty International also accused some African governments of using COVID health protocols to control or punish their citizens.

Jackson says the government used lockdowns and restrictions of movement to abuse people.

“We’ve seen a number of governments in the region, particularly the year before 2020 but also sometimes in 2021, have limited right to freedom of assembly,” Jackson said. “I am thinking in Ugandan context around the Uganda elections in the name of COVID-19, and this impacted the rights of citizens to organize to assemble.”

Amnesty International is calling on African citizens to stand up for their rights and resist any attempt to muzzle their voices. The rights group will be launching a global campaign demanding respect for the right to protest.

Source: Voice of America

Fighting Impunity Key to National Reconciliation in Central African Republic

A new report on the human rights situation in the Central African Republic says combating impunity is key to achieving national reconciliation and a durable peace in the war-torn country. The report from a U.N. investigator was submitted to the U.N. Human Rights Council on Monday.

The report says atrocities and human rights violations continue to be committed by various armed groups in the Central African Republic, including by the mainly Muslim ex-Seleka, the largely Christian anti-Balaka, and FACA, the Armed Forces of the C.A.R.

U.N. investigator Yao Agbetse accuses them of pillaging and looting villages and of threatening the civilian population with violence to exact illegal taxes.

He expresses particular concern about reports of ongoing human rights abuse by Russian mercenaries employed by the Wagner Group, a private security company, which reportedly has close ties with FACA.

He says witnesses have reported many crimes perpetrated by the mercenaries. Agbetse told the council they include sexual violence, intimidation, destruction of homes, racketeering, and torture.

“The Russian bi-lateral forces have also hindered investigations where violations of human rights were committed… As regards contractual relations with the C.A.R., under international law, the Russian bi-lateral forces are not a recognized international body,” he said.

Therefore, said Agbetse, the responsibility for violations falls on the Central African Republic government, which must take all measures to achieve justice for the victims.

In response, C.A.R. Minister of Justice Djoubaye Abazene told the U.N. council that his government is making major reforms. He says it is improving the security sector and has a new judicial and court system, which is working to shed light on allegations of human rights abuse.

“Investigations are now open for all presumed allegations in cases of human rights violations. Whoever the perpetrators may be and whatever their positions may be, they will be brought to justice and punished. You can be reassured of that,” he said.

The president of the C.A.R. Truth, Justice and Reparations Committee, Marie-Edith Douzima, said 87% of the population thinks it is possible to have lasting peace in the C.A.R. — providing those responsible for violence are punished.

She said it is vital to combat impunity for the C.A.R. to find a way out of the repeated crises afflicting the country. She noted that to date, no victims of sexual or other crimes have received compensation and reparations. That wrong, she added, must be rectified.

Source: Voice of America

Ben Frederickson: Dodger Blue blueprint should be Cardinals plan for Pujols

Published by
St. Louis Post-Dispatch

JUPITER, Fla. — The potential fit had been there, sitting and waiting, wondering if both sides would come to see it the same way. Now we know that answer is yes, and so begins the final chapter between Albert Pujols and the Cardinals. The Reunion. Pujols became one of the greatest righthanded hitters of all time as a drafted-and-developed Cardinal. He shattered hearts when he left for the Angels after the 2011 World Series championship, chasing bigger money out west, where he never was the same, while the team he left behind tried but failed to prove it could reach baseball’s World Series moun… Continue reading “Ben Frederickson: Dodger Blue blueprint should be Cardinals plan for Pujols”

Conagen’s Grant Award Opens New Markets for Monoclonal Antibodies

Funding from the Bill & Melinda Gates Foundation for Conagen’s Conamax platform benefits developing countries and patients globally.

Bedford, Mass., March 29, 2022 (GLOBE NEWSWIRE) — The Bill & Melinda Gates Foundation has given a grant to Conagen to support further development of its Conamax(TM) platform for the production of accessible low-cost and high-quality monoclonal antibodies, benefitting developing countries and patients globally.

The high cost of monoclonal antibody (mAb) production makes blockbuster drugs expensive, limiting the markets in which these molecules can be applied and limiting access to large patient populations in developing and industrialized countries. The reason for high production costs is, in part, intrinsic to the use of mammalian cell expression systems for antibody manufacturing.

“The Conamax platform was originally conceived to address this global unmet need, so we are thrilled to have the support of the Bill & Melinda Gates Foundation to help develop affordable antibody therapeutics,” said Casey Lippmeier, Ph.D., vice president of innovation at Conagen.

With rapid cell growth, human-compatible glycan structures, and demonstrated world-scale fermentation bioprocesses, the Conamax platform holds several advantages over Chinese Hamster Ovary (CHO) cell lines and other mammalian expression systems, as well as other microbial platforms.

The foundation grant funds the bench-scale development of a proof-of-concept study of a continuous purification process, customized to inputs from Conamax and potentially other microbial host organisms. With large-scale advancements, Conagen envisions that this process will be capable of continuously purifying mAbs from material generated in bioreactors with volumes greater than 250,000 liters.

As a significant advantage, the process will not require expensive binding proteins or other expensive column purification steps. This process will enable economies of scale which are not accessible to CHO or other mammalian-derived cell systems while also providing rapid, high-throughput purification of large amounts of antibody.

“Incumbent antibody manufacturing and purification processes based on Chinese Hamster Ovary (CHO) cell lines have brought tremendous advancements to biopharmaceuticals,” said Lippmeier. “However, CHO cell systems are comparatively low volume, expensive, and do not enable low cost and efficient purification of large amounts of antibodies.”

According to McKinsey, in 2019, global sales revenue for all mAb drugs was nearly $163 billion, representing about 70% of the total sales for all biopharmaceutical products, approximately $230 billion. That is about a 50% growth in sales and proportion since 2013, when it was $75 billion.

Continued growth in sales of currently approved mAb products, along with more than 1,200 mAb product candidates currently in development — many for multiple indications — will continue to drive the overall sales of all biopharmaceutical products.

“We’re unlocking the way to make drugs more affordable and, while doing so, opening additional markets for biologics,” said Lippmeier.

###

About Conagen
Conagen is a product-focused synthetic biology R&D company with large-scale manufacturing service capabilities. Our scientists and engineers use the latest synthetic biology tools to develop high-quality, sustainable, nature-based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

Attachment

Ana Arakelian, head of public relations and communications
Conagen
+1.781.271.1588
ana.arakelian@conagen.com

LeddarTech Will Unlock the Value of Raw Data Fusion and Perception at Automotive Tech.AD Berlin (Germany) on April 3-5, 2022

Environmental perception technology for safer autonomous driving with better detection

QUEBEC CITY, March 29, 2022 (GLOBE NEWSWIRE) — LeddarTech®, a global leader in providing the most flexible, robust and accurate ADAS and AD sensing technology, is pleased to announce its participation at Automotive Tech.AD Berlin at the Titanic Chaussee Hotel Berlin as an exhibitor and keynote speaker.

April 4-5, 2022: LeddarTech’s LeddarVision™ Demonstrator Space (live and virtual)

Join the LeddarTech team for real-world demonstrations of LeddarVision. The only sensor fusion and perception software using raw data fusion that simplifies complex sensor sets eliminates the dependency on hardware and provides customers the flexibility to quickly scale solutions across vehicle models, delivering greater ADAS and AD performance.

Meet the CTO of LeddarTech, Pierre Olivier, a pioneer in sensing with over 30 years of experience presenting at these events during the conference:

  • Sunday, April 3, 2022, 19:45 – 23:00 CET: Icebreaker Session

Topic: The Road to Full Automation – Progress and Challenges

  • Monday, April 4, 2022, 10:00 – 10:30 CET: Presentation

Topic: Sensing and Perception Technology – Solutions That Solve Critical Sensing Challenges

Learn about LeddarVision, a raw-data sensor fusion and perception platform that generates a comprehensive 3D RGBD environmental model with multi-sensor support for camera, radar and LiDAR configurations. This software-centric solution delivers superior perception performance exhibited through path planning, free space detection and enhanced object detection, tracking and classification.

About Automotive Tech.AD Berlin

Tech.AD Europe fuels you with new ideas, connections and inspiration. This event is directed at advanced engineers and automotive experts from OEMs, Tier 1s, automotive suppliers, solution providers and leading research institutes focusing on AI + machine learning, sensor and perception technologies, software architectures and AV platforms, testing and validation, commercial vehicles and early deployment, connectivity and 5G, infrastructures and smart cities, safety and security and more. Join over 500 of the most influential technical autonomous vehicle experts and executives in Berlin and online! Join LeddarTech either in person or digitally by registering today at https://www.autonomous-driving-berlin.com/.

About LeddarTech

Founded in 2007, LeddarTech is a comprehensive end-to-end environmental sensing company that enables customers to solve critical sensing, fusion and perception challenges across the entire value chain. LeddarTech provides cost-effective perception solutions scalable from Level 2+ ADAS to Level 5 full autonomy with LeddarVision™, a raw-data sensor fusion and perception platform that generates a comprehensive 3D environmental model from a variety of sensor types and configurations. LeddarTech also supports LiDAR manufacturers and Tier 1-2 automotive suppliers with key technology building blocks such as LeddarSteer™ digital beam steering and the LiDAR XLRator™, a development solution for automotive-grade solid-state LiDARs based on the LeddarEngine™ and core components from global semiconductor partners. The company is responsible for several innovations in cutting-edge automotive and mobility remote-sensing applications, with over 100 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook and YouTube.

Contact:
Daniel Aitken, Vice-President, Global Marketing, Communications and Investor Relations, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232
daniel.aitken@leddartech.com

Investor Relations contact : InvestorRelations@leddartech.com
https://investors.leddartech.com/

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, LeddarEcho, VAYADrive, VayaVision, XLRator and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.